Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Reneo Pharmaceuticals Q4 GAAP EPS $(0.70) Misses $(0.62) Estimate; Cash, Cash Equivalents, And Short-term Investments Of $103M
Reneo Pharmicals第四季度GAAP每股收益美元（0.70）未達到預期（0.62）；現金、現金等價物和短期投資爲1.03億美元
Reneo Pharmaceuticals (NASDAQ:RPHM) reported quarterly losses of $(0.70) per share which missed the analyst consensus estimate of $(0.62) by 12.9 percent. This is a 25 percent decrease over losses of $(0.56) per share from the same period last year.
Reneo Pharmicals（納斯達克股票代碼：RPHM）公佈的季度虧損爲每股0.70美元，比分析師普遍預期的0.62美元（0.62美元）低12.9％。這比去年同期每股虧損0.56美元（0.56美元）下降了25％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。